Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/24329
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Pignatelli, Miguel | - |
dc.contributor.author | Cortés-Canteli, Marta | - |
dc.contributor.author | Lai, Cary | - |
dc.contributor.author | Santos, Ángel | - |
dc.contributor.author | Pérez Castillo, Ana | - |
dc.date.accessioned | 2010-05-14T10:42:49Z | - |
dc.date.available | 2010-05-14T10:42:49Z | - |
dc.date.issued | 2001-11 | - |
dc.identifier.citation | Journal of Cell Science 114(22): 4117-4126 (2001) | en_US |
dc.identifier.issn | 0021-9533 | - |
dc.identifier.uri | http://hdl.handle.net/10261/24329 | - |
dc.description | 10 pages, 8 figures.-- Research article. | en_US |
dc.description.abstract | One of the most interesting recent developments in the nuclear receptor field has been the identification of natural and synthetic agonists of the peroxisome proliferator-activated receptor (PPAR) family, coupled with a growing recognition that the gamma isoform (PPARgamma) affects pathways important in a variety of human diseases. Here we show that the activation of PPARgamma through the 15-deoxy-Delta-12,14-prostaglandin J(2) (PG-J(2)) ligand causes a dramatic inhibition of ErbB-2 and ErbB-3 tyrosine phosphorylation caused by neuregulin 1 (NRG1) and neuregulin 2 (NRG2) in MCF-7 cells. This effect is accompanied by a very efficient blocking of ErbBs effects upon proliferation, differentiation and cell death in these cells. Preincubation of MCF-7 cells with PG-J(2) before addition of NRG1 and NRG2 had a dramatic growth-suppressive effect accompanied by accumulation of cells in the G0/G1 compartment of the cell cycle, and a marked increase in apoptosis. NRG1 and NRG2 induce G1 progression, which was associated with stimulation of the phosphatidylinositol-3 kinase (PI 3-K) pathway, whereas survival was dependent on ERK1/ERK2 activation. Both pathways were inhibited by PG-J(2). Furthermore, PG-J(2) can abolish the NRG1 and NRG2-induced increase in anchorage-independent growth of these cells. PG-J(2) also blocks phosphorylation of other receptor tyrosine kinases, such as IGF-IR, in MCF-7 cells, and suppress proliferation of other breast cancer cell lines. In summary, our data show a specific inhibitory action of PG-J(2) on the activity of the ErbB receptors in breast cancer cells. | en_US |
dc.description.sponsorship | This work has been supported by Grants from the Dirección General de Enseñanza Superior e Investigación Científica, Grants PM97-0063 (A.P.-C.) and PM96-0051 (A.S.) and by the Comunidad de Madrid, Grant 08.5/0003/1997 (A.P.-C. and A.S.). M.P. is a fellow of the Fondo de Investigaciones Sanitarias de la Seguridad Social. M.C.-C. has a fellowship from the Comunidad de Madrid. | en_US |
dc.format.extent | 802840 bytes | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | en_US |
dc.publisher | Company of Biologists | en_US |
dc.rights | closedAccess | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | ErbBs | en_US |
dc.subject | Phosphorylation | en_US |
dc.subject | PPAR(gamma) | en_US |
dc.subject | Transformation | en_US |
dc.title | The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells | en_US |
dc.type | artículo | en_US |
dc.description.peerreviewed | Peer reviewed | en_US |
dc.relation.publisherversion | http://jcs.biologists.org/cgi/content/full/114/22/4117 | en_US |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.openairetype | artículo | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
Aparece en las colecciones: | (IIBM) Artículos |
CORE Recommender
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.